Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 3,501–3,600 of 4,275
Immune checkpoint inhibition in the context of aging
Baxevanis, C. N., & Tsitsilonis, O. (2025) · Ageing and Cancer Research & Treatment · doi:10.70401/acrt.2025.0002 · Cited by 1
Aging rate indicators and the search for anti-aging drugs
Austad, S. N., Kaeberlein, M. R., & Miller, R. A. (2026) · Frontiers in Science · doi:10.3389/fsci.2026.1821393 · Cited by 4
The Role of Stem Cell Genomic Instability in Aging
Sieben, C. J., Childs, B. G., & Baker, D. J. (2015) · Current Stem Cell Reports · doi:10.1007/s40778-015-0020-6 · Cited by 1
Watanabe, L. O., de Sousa, L. B., Melo, M. E. S., da Silva, J. C., Cardoso, L. R., de Carvalho, M. R. C., Fidelis, D. K. R., Karajeh, S. S. A., da Silva, I. G. M., Corrêa, J. R., et al. (2026) · Journal of Endodontics · doi:10.1016/j.joen.2026.07.002 · Cited by 1
Potential Applications of Aptamers for Targeting Senescent Cells
Leonardi, A., Pacifico, F., & Crescenzi, E. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_10 · Cited by 1
Subtype-Specific SASP Dynamics Predict Mesenchymal Transition in Recurrent GlioblastomaPreprint
Kotagiri, V., & Teng, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699753 · Cited by 1
“Senescent cells remain metabolically active and secrete a complex mixture of cytokines (IL-6, IL-1β), chemokines (CCL2, CXCL8), growth factors (HGF, VEGF), and matrix metalloproteinases collectively termed the senescence-associated secretory phenotype (SASP) [3,4] .”
Niklasson, M., Dalmo, E., Segerman, A., Rendo, V., & Westermark, B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.20.599819 · Cited by 2
Insulin-Like-Growth Factor-Binding-Protein 7: An Antagonist to Breast Cancer
Benatar, T., Amemiya, Y., Yang, W., & Seth, A. K. (2011) · InTech eBooks · doi:10.5772/21700 · Cited by 1
“Together, these secreted factors are referred to as the Senescence-Messaging Secretome (SMS) or the Senescence- Associated Secretory Phenotype (SASP) [79,78].”
BackgroundIdentification of novel key markers that are induced during traumatic brain injury in mice
Li, Y., Li, N., Luan, C., Pei, Y., Zheng, Q., Yan, B., Ma, X., & Liu, W. (2023) · PeerJ · doi:10.7717/peerj.15981 · Cited by 1
“Senescent cells have been known to secret chemokines and in fl ammatory factors via its senescence associated secretory phenotype (SASP), which are commonly triggered by nuclear factor kappa B (NF-κ B) signaling, during development of age related diseases ( Coppe et al., 2008 ).”
Balancing senescence and apoptosis: therapeutic insights into aging and cancer
Jan, N., Sofi, S., Mir, A. A., Masoodi, G., & Mir, M. A. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05355-3 · Cited by 4
Precision medicine to manage chronic immune-related conditions
Gibson, D. S., Egan, P., Guo, G., Kelly, C., McClean, P. L., McGilligan, V., McAllister, R., Matchett, K. B., Martin, C. A., Murray, E. K., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00009-8 · Cited by 1
Epigenetic dynamics of cellular senescence: From mechanistic insights to precision senotherapy
Hu, X., Lai, W., Liu, M., & Wang, B. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004042 · Cited by 2
“22–24] Based on this, drugs that can attenuate the deleterious consequences of the SASP and reduce senescence-induced inflammation without killing SnCs such as rapamycin were summarized in 2019, which were named senomorphics.”
IRE1α drives lung epithelial progenitor dysfunction to establish a niche for pulmonary fibrosis
Auyeung, V., Downey, M. S., Kathiriya, J., Thamsen, M., Wenger, T. A., Backes, B., Brumwell, A., Chapman, H., Sheppard, D., & Papa, F. R. (2021) · bioRxiv · doi:10.1101/2021.09.16.460705 · Cited by 20
Payea, M. J., Gorospe, M., & Basisty, N. (2022) · Journal of Visualized Experiments · doi:10.3791/63835-v · Cited by 1
Olinger, B., & Basisty, N. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103254 · Cited by 2
Pundlik, S. S., Sahoo, S. S., Barik, A., Venkateshvaran, A., Jaysingh, M. A., Math, R. G. H., & Ramanathan, A. (2024) · eLife · doi:10.7554/elife.95229.1 · Cited by 1
Yao, M., Wu, Y., Cao, Y., Liu, H., Ma, N., Chai, Y., Zhang, S., Zhang, H., Nong, L., Li, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-201782/v1 · Cited by 1
Cell type-dependent modulation of senescence features using Weo electrolyzed water
Court-Vazquez, B. L., Arroyo-Vizcarrondo, S. A., Poli, J. A., Nyman, L. R., Halderman, K., Ginter, A., & Desprez, P. (2024) · Aging · doi:10.18632/aging.205789 · Cited by 1
Self-citationFrom systemic disease to the eye: Why senescence deserves attention in ocular infections
Maiti, S., & Joseph, J. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111095 · Cited by 1
Cheng, Z., Guo, T., Liu, B., & Liu, X. X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004589 · Cited by 2
“Senescent cells secrete numerous pro-inflammatory cytokines and chemokines, including IL-6 and IL-8, thereby inducing inflammation in surrounding tissues [ 62 , 63 ] .”
T Cell Senescence and Tumor Immunotherapy
Liu, X., & Peng, G. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_136 · Cited by 1
Oral Cancer: Recent Developments and Future Challenges
Parkinson, E. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-56065-6_8 · Cited by 1
Adipocytes as core drivers of skin aging and novel targets for regeneration
Wang, E., Xu, Z., Wang, Y., Wang, J., Jiang, Y., & Zhao, C. (2026) · Biogerontology · doi:10.1007/s10522-026-10413-4 · Cited by 2
“…its composition is highly heterogeneous and is shaped dynamically by cell type, the senescence-inducing stimulus, and time after senescence onset (Coppé et al. 2008 In skin biology, secondary senescence is a useful framework because senescent cells can propagate stress and senescence programs to…”
Wilmouth, J., Olabe, J., García-García, D., Lucas, C., Guiton, R., Roucher‐Boulez, F., Dufour, D., Damon‐Soubeyrand, C., Sahut‐Barnola, I., Pointud, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.29.489846 · Cited by 1
Stem cells, fitness, and aging
Kitaeva, K. V., Kiyasov, A. P., Rizvanov, A. A., Rutland, C. S., & Solovyeva, V. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00007-0 · Cited by 1
Le fibroblaste sénescent : un catalyseur de la tumorigenèse
Brassart‐Pasco, S., & Hornebeck, W. (2012) · Médecine & longévité · doi:10.1016/j.mlong.2012.02.004 · Cited by 1
The lncRNA MIR31HG regulates the senescence associated secretory phenotype
(2020) · doi:10.21203/rs.3.rs-57840/v1 · Cited by 1
“On the other hand, the SASP can promote tumorigenic processes such as angiogenesis and invasion (Coppe et al., 2008, Krtolica, Parrinello et al., 2001).”
BackgroundFaculty Opinions recommendation of Astrocyte senescence: Evidence and significance.
Rattan, S. I. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735180286.793557427 · Cited by 1
Imaoka, H., Ikeda, M., Wakabayashi, M., Umemoto, K., Satake, T., Sunakawa, Y., Ueno, H., Hara, K., Nagashima, F., Kataoka, S., et al. (2026) · Cancers · doi:10.3390/cancers18111818 · Cited by 1
“However, in the tumor microenvironment, chronic senescence can paradoxically promote cancer progression through sustained inflammatory signaling [48].”
Lyu, W., Wang, H., Du, Z., Wei, R., He, J., Meng, F., Bi, J., Zhang, L., Zhang, C., Guan, Y., et al. (2025) · eLife · doi:10.7554/elife.104774.3 · Cited by 2
“The disruption of signaling pathways disrupts tissue homeostasis, leading to proinflammatory responses that are increasingly recognized as fundamental aspects of senescence ( Coppé et al., 2008 ; Shah et al., 2013 ).”
InfluentialBridging Biochemistry and Aging: A Journey Towards Prolonged Health span
Panchal, N. (2024) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3226 · Cited by 2
Zhou, Y., Zhu, H., Zhao, L., Zhao, G., & Sun, J. (2025) · Medicine · doi:10.1097/md.0000000000042245 · Cited by 1
“This includes enhancing blood vessel formation in tumors, [69] facilitating the spread and migration of cancer cells, [70] and triggering epithelial-to-mesenchymal transition in nearby cells to support tumor invasion.”
Qiu, S., Hu, Y., Wang, Y., Xian, H., & Yin, Q. (2026) · BMC Cancer · doi:10.1186/s12885-025-15517-7 · Cited by 1
The Toxin of the Year: Airborne PM 2.5
Rolfes, K. M., Singh, N., Haarmann‐Stemmann, T., & Krutmann, J. (2025) · Dermatitis · doi:10.1177/17103568251385571 · Cited by 1
“118 In dermal fi broblasts, a speci fi c subset of secreted proteins termed skin aging-associated secreted proteins has been identi fi ed.”
Radiation-induced senescent melanoma cells secrete soluble factors that trigger bystander senescence
Salvarredi, L. A., Agüero, H., Millán, M., Marra, M. F., Callegari, E. A., Castro, C., & Lopez, L. (2025) · International Journal of Radiation Biology · doi:10.1080/09553002.2025.2505525 · Cited by 2
“Initial studies focused on its pro-tumorigenic properties (Krtolica et al. 2001; Coppé et al. 2006; 2008), but important tumor suppressive effects have been reported (Kuilman and Peeper 2009).”
Rosenblum, J. I., Toscanella, F., Avrahami, R., Rosenblum, S., & Eng, D. (2017) · Journal of Clinical & Experimental Dermatology Research · doi:10.4172/2155-9554.1000405 · Cited by 1
Molecular Mechanisms of Cardiovascular Aging
Meiliana, A., & Wijaya, A. (2013) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v5i3.64 · Cited by 1
“(25,26) SASP is primarily a DNA Damage Response (DDR).”
BackgroundJumonji C Demethylases in Cellular Senescence
(2018) · doi:10.20944/preprints201811.0382.v1 · Cited by 1
Hypoxia and Senescence: Role of Oxygen in Modulation of Tumor Suppression
Eren, M. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-0313-9_5 · Cited by 1
Inflammaging: Expanding the Molecular Palette of Cellular ImmunophenotypePreprint
Иванов, Д. О., Дробинцева, А. О., Rodichkina, V. R., Mironova, E. S., Zubareva, T. S., Krylova, Y. S., Morozkina, S. N., Nasyrov, R. A., & Kvetnoy, I. M. (2024) · Preprints.org · doi:10.20944/preprints202404.0644.v1 · Cited by 1
Systematic transcriptomic analysis and temporal modelling of the senescent human fibroblastPreprint
Scanlan, R.-L., Pease, L., O’Keefe, H., Guimera, A. M., Shanley, D., & Wordsworth, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.16.504144 · Cited by 1
“However, inflammatory proteins are expressed immediately upon senescence induc6on in sub-model B simula6ons which is not reflected in the literature (Coppé et al., 2008; Hoare et al., 2016) or our systema6c analysis ( Figure 10A-C ).”
BackgroundFármacos senolíticos. ¿La base del rejuvenecimiento inteligente?
Eduvigis Solórzano, N. (2022) · Acta Bioclínica · doi:10.53766/acbio/2022.12.23.01
Predictive genomic biomarkers of therapeutic effects in renal cell carcinoma
Yan, W., Hou, N., Zheng, J., & Zhai, W. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00827-4 · Cited by 1
“…of P53 to produce senescence-associated secretory phenotype (SASP) under physiological circumstances [77], mutated P53 in tumor cells may lead to longer uncontrolled SASP response, which can lead to IL-6 and IL-8 secretions and increased angiogenesis, resulting in tumor progression [78–80].”
Telomere Dynamics and Aging Related Diseases
Toupance, S., & Bénétos, A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316677018.007 · Cited by 1
Senolytic potential of shea-derived amyrins in senescent fibroblasts
Hirose, M., Watanabe, S., Fujita, Y., Ohta, S., & Sugimoto, M. (2025) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaf153 · Cited by 1
Introduction to Ex Vivo Cancer Models
Jenkins, R. W. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-45397-2_1 · Cited by 1
Parikh, C. N., DeMarco, K. D., Bhalerao, N., Giwa, H. K., Kane, G. I., Dinnell, R. W., Ma, B., Mori, H., Brassil, M. L., Murphy, K. C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74574-z · Cited by 4
Yin, Y., Liu, Y., Lu, Y., Tang, Z., Zhu, Z., Zhu, M., Chen, H., Hui, H., Xu, J., & Li, H. (2025) · The FASEB Journal · doi:10.1096/fj.202500962rr · Cited by 1
Kochetkova, E. Y., Pospelov, V. A., & Pospelova, T. V. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2071-7_10 · Cited by 1
Robert, M., Jakhar, R., Au, B. V., Eng, G. W. L., Wei, M., Gao, A. K., Chuah, Y. H., Sachaphibulkij, K., Bonne, I., Lim, K. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.29.586905 · Cited by 1
Review the Molecular Mechanism of Aging and the Role in Neurodegenerative DiseasesPreprint
Zhao, J., Han, Z.-J., Ding, L., Wang, P., He, X., & Li, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4530191 · Cited by 1
Zhou, Q.-J., Geng, Z., Lian, S., Wang, J., & Wu, R. (2025) · Animals · doi:10.3390/ani15101419 · Cited by 3
Photocatalysis in the Skin Related to UVA Photoaging
Yoshimoto, S., Yoshida, M., & Ichihashi, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107445 · Cited by 3
Luo, X., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848488 · Cited by 1
Zhong, S., Wu, D., Chen, Q., Zeng, C., Chen, H., & Huang, J. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102624 · Cited by 1
Nitric oxide redox signaling as a convergent mechanism in aging and fibrosis
Guo, X., Cao, Y., Liu, L., Peng, Y., Du, Y., Yang, F., & Huang, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103156 · Cited by 1
Acetylation-Dependent Histone H2AX Exchange Suppresses Pathological Senescence via MDC1 Degradation
Ikura, M., Furuya, K., Horikoshi, Y., Tashiro, S., SHIRAKI, T., & Ikura, T. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2596729 · Cited by 1
Sex and stimulus-specific differences in endothelial cell senescence under hormone-free conditions
Quarder, A., Talbi, K., Bartmann, H., Beuke, E., von Kaisenberg, C., Vincente, M. M., Todorovic, S., & Melk, A. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2025 · Cited by 3
Therapy Induced Senescence Promote Expression of Death Receptors in Breast Cancer Cells
Eren, M. K., Pilevneli, H., Ak, C., Karlıtepe, A., & Kaygusuz, N. (2021) · Tıpta Yenilikçi Yaklaşımlar Dergisi · doi:10.29329/jiam.2020.299.1 · Cited by 2
Dou, X., Long, Q., Liu, S., Zou, Y., Fu, D., Chen, X., Xu, Q., Wang, C., Ren, X., Zhang, G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.21203/rs.3.rs-1966019/v1 · Cited by 2
Self-citationWei, Z., Li, Z., & Quan, N. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1702207 · Cited by 1
Cytokine Expression and Production Changes in Very Old Age
McNerlan, S., Ross, O. A., & Rea, I. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_40-1 · Cited by 1
Human Cytomegalovirus as a driving force towards Immunosenescence
Zadražil, Z. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/73417 · Cited by 1
“SASP cell accumulation does not only contribute to local tissue damage, but may contribute to or establish the chronic low-grade inflammation status observed in the elderly.”
BackgroundInfluentialCellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers
Cai, G., Ren, J., Wang, L., Wu, Y., Wang, H., Cao, X., Shang, H., Hou, X., Wang, Y., Xue, H., et al. (2026) · MedComm · doi:10.1002/mco2.70827 · Cited by 2
“Senescence is defined by permanent cell cycle arrest and the senescence-associated secretory phenotype (SASP), a heterogeneous cocktail of cytokines, chemokines, growth factors, and proteases [ 2 ].”
InfluentialImpact of exercise-induced DNA damage repair on age-related muscle weakness and sarcopenia
朱, 玲., Su, Y., & Su, Z. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1639224 · Cited by 3
Cherqui, U., Sopher, I., Akiva, H., Menahem, O., Kopitman, E., Blecher‐Gonen, R., Keren‐Shaul, H., Rachmian, N., Mayo, A., Alon, U., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.14.688272 · Cited by 1
Identification of key genes and immune characteristics of SASP in acute ischemic strokePreprint
Cai, H., Zhang, H., Xin, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4895771/v1 · Cited by 1
Lee, J., Lee, S., Kim, K., Park, K., & Park, K. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1137-9 · Cited by 2
Aronoff, J. E., Franck, M., Cohen, A. A., & Trumble, B. C. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag119 · Cited by 2
Regulation of Forkhead BOX O tumor suppressors by Reactive Oxygen Species
de Keizer, P. L. J. (2009) · Utrecht University Repository (Utrecht University) · Cited by 1
Exploring the role of cellular senescence in cancer prognosis across multiple tumor types
Xu, Q., & Feng, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1378356 · Cited by 1
Cellular senescence in lung cancer immune microenvironment and senotherapeutic opportunities
Xu, Z., Liu, F., Huang, S., & Chu, Q. (2026) · iScience · doi:10.1016/j.isci.2026.114673 · Cited by 4
The role of telomere damage in cardiomyocyte ageing
Anderson, R. K. (2016) · Cited by 1
Modeling CIC::DUX4 sarcoma reveals oncogene-mediated MHCI-dependent immune evasion
Vachanaram, A. R., Wei, E., Mitanoska, A., Bassett, W., Kyba, M., & Bosnakovski, D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02485-6 · Cited by 2
“G Volcano plot of differentially expressed cellular senescence-associated genes (highlighted in red) from a curated list of 125 genes from the SenMayo dataset [37] and 54 SASP-related genes identified by Coppé et al. [38] in imChCDS cells after 72 h of dox withdrawal.”
Temporal evaluation of an ex vivo bioreactor model of abdominal aortic aneurysm
Clark, E. R. (2016) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Heterotopic bone formation derived from multipotent stromal cells is not inhibited in aged mice
Carbonneau, C. L., Despars, G., Moquin‐Beaudry, G., Benabdallah, B., Bouhanik, S., Dépôt, J., Moreau, A., & Beausejour, C. M. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.004 · Cited by 1
Moving from reactive to preventive medicine
Badimón, L., Padró, T., & Vilahur, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00003-3 · Cited by 1
Biological Impact of Senescence Induction in Prostate Cancer
Jarrard, D. F. (2010) · Defense Technical Information Center (DTIC) · doi:10.21236/ada551887 · Cited by 1
Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis
Kuehnemann, C., Jezak, S. T., Mogck, B. A., Kura, N., Tariq, R., Che, Y., Vaittinen, M., Siokas, I., Deshpande, S., Guthrie, C., et al. (2026) · Cell · doi:10.1101/2024.10.03.616257 · Cited by 1
Long-term exposure to carbon nanotubes accelerates systemic aging in mice
Huang, C., Liu, X., & Song, Y. (2025) · Journal of Environmental Sciences · doi:10.1016/j.jes.2025.05.059 · Cited by 1
Pancreatic β-Cell Senescence: A Contributor to Type 2 Diabetes
Urmi, R., Singh, R., Singh, M., & Sinha, B. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-1041-9_8 · Cited by 1
Severe COVID-19 and Telomere Shortening: Overview of Roles and Effects
Chen, S. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.1212015 · Cited by 2
Cancer, Senescence, and Aging: Translation from Basic Research to Clinics
LLeonart, M. E., Carnero, A., Paciucci, R., Wang, Z., & Shomron, N. (2011) · Journal of Aging Research · doi:10.4061/2011/692301 · Cited by 3
“It follows that at the presenescence phase, the amount of the p53/p21 growth inhibitor appears insufficient to downregulate NANOG, which may to some extent neutralise p16 and that, therefore, more time (or activation of more p53 activators including for example, the p38 pathway [16, 49]) is needed for p53 to become an…”
BackgroundInfluentialAging and Malignant Hemopathies: A Complex Multistep Process
Chi, V. L. D., Sibille, C., Willard-Gallo, K. E., & Bron, D. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_142-1 · Cited by 1
Pérez‐Pons, A., Henriques, A., Sanfeliciano, T. C., Jara‐Acevedo, M., Navarro‐Navarro, P., García‐Montero, A. C., Álvarez‐Twöse, I., Lécrevisse, Q., Fluxá, R., Sánchez‐Muñoz, L., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.10.005 · Cited by 3
Caligiuri, A., & Marra, F. (2015) · Wiley eBooks · doi:10.1002/9781118663387.ch3 · Cited by 2
(2020) · doi:10.1101/2020.07.06.189019 · Cited by 1
“This includes a number of pro-inflammatory cytokines, including IL-6 and IL-8, molecules known to induce EMT and invasion of pre-malignant cells (Malaquin et al., 2013, Coppe et al., 2008, Ortiz-Montero et al., 2017, Lau et al., 2019).”
BackgroundInfluentialDimri, M., & Dimri, G. P. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0025372 · Cited by 1
Exploring the Interplay Between Senescent Osteocytes and Bone Remodeling in Young Rodents
Song, I., Kim, P.-J., Choi, Y. J., Chung, Y., Lee, S., Baek, J., & Woo, K. M. (2024) · Journal of Aging Research · doi:10.1155/2024/4213141 · Cited by 2
p16 Beyond Senescence: Cancer Biology Lessons Applied to Endometriosis
Kobayashi, H. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02134-3 · Cited by 1
“SASP induction is initiated by the DNA damage response and regulated by nuclear factor kappa B (NF-κB), CCAAT/enhancer-binding protein beta, and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways [13, 20].”
Reina-Gonzalez, P., Ay, M., Langley, M. R., Plunk, E. C., Strazdins, R., Abu-Salah, A., Anchan, A., Shah, A., & Sarkar, S. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf088 · Cited by 2
Senescent cells secrete chromatin components via senescence-associated extracellular particlesPreprint
Adams, P. D., Zaretski, S., Torres, J. L. N., Lei, X., Nolan, J., & Hansen, M. (2025) · Research Square · doi:10.64898/2025.12.12.694055 · Cited by 5
Sex and the Aging Immune System
Gibson, D. C., & Bupp, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00059-2 · Cited by 2
Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
Meroni, M., Dongiovanni, P., Longo, M., Rametta, R., Badiali, S., Fargion, S., Romeo, S., Gatti, S., & Valenti, L. V. C. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30280-0 · Cited by 1
“7) Total cholesterol, mg/dL 205±39 LDL cholesterol, mg/dL 127±37 HDL cholesterol, mg/dL 45±11 Triglycerides, mg/dL 147±78 ALT, IU/l 50 [18-75]”
Wang, L., Dong, X., Yu, L., Jie, H., Wang, B., Li, L., Chen, J., Liu, M., & Dong, B. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025185 · Cited by 2
Basu, A., Farsam, V., Singh, K., Crișan, D., Treiber, N., Schneider, L. A., Huber, M. A., Engelmeyer, J. I., Schumacher, B., Maity, P., et al. (2025) · Aging Cell · doi:10.1111/acel.70239 · Cited by 1
“To identify SASP factors released by senescent fibroblasts which promote tumor progression, young non-senescent and replicative senescent fibroblasts and the CM thereof were subjected to complementary qPCR-based transcriptome analyses (RT 2 Profiler, Cat.”
Influential
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.